ANDORASIROX 500MG 20TABS. FOR ORAL SUSP

ABOUT DEFERASIROX A SYNTHETIC ACHIRAL TRIDENTATE TRIAZOLE DERIVED FROM SALICYLIC ACID ORAL IRON CHELATING AGENTS. INDICATION FOR THE TREATMENT OF CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS (TRANSFUSIONAL HEMOSIDEROSIS) IN PATIENTS 2 YEARS OF AGE AND OLDER. MECHANISM OF ACTION TWO MOLECULES OF DEFERASIROX ARE CAPABLE OF BINDING TO 1 ATOM OF IRON. DEFERASIROX WORKS IN TREATING IRON TOXICITY BY BINDING TRIVALENT (FERRIC) IRON (FOR WHICH IT HAS A STRONG AFFINITY) FORMING A STABLE COMPLEX WHICH IS ELIMINATED VIA THE KIDNEYS.